We recently published a list of 7 Best ASX Stocks To Invest In Right Now. In this article, we are going to take a look at ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

According to a report by the Australian Bureau of Statistics, Australia’s economy is growing at a sluggish pace as GDP for ...

A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer.

Angiogenesis plays a major role in cancer and VEGF-targeted agents have been shown to be useful in advanced-stage malignancies. Current antitumor cancer drugs targeting the HER and VEGF ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Instil Bio, Inc. (NASDAQ:TIL) recently traded higher on the back of analyst raising their price target on shares because of how much the PD-1/VEGF bispecific antibody space is heating up.

D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on ...

Diabetic Macular Edema Market valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034.